Alp Aytekin, Maria Scalamogna, J J Coughlan, Shqipdona Lahu, Gjin Ndrepepa, Maurizio Menichelli, Katharina Mayer, Jochen Wöhrle, Isabell Bernlochner, Bernhard Witzenbichler, Willibald Hochholzer, Dirk Sibbing, Dominick J Angiolillo, Rayyan Hemetsberger, Ralph Tölg, Christian Valina, Arne Müller, Sebastian Kufner, Christoph Liebetrau, Erion Xhepa, Alexander Hapfelmeier, Hendrik B Sager, Michael Joner, Gert Richardt, Karl-Ludwig Laugwitz, Franz Josef Neumann, Heribert Schunkert, Stefanie Schüpke, Adnan Kastrati, Salvatore Cassese
BACKGROUND: The ISAR-REACT 5 trial compared the efficacy and safety of ticagrelor and prasugrel in patients with ACS managed invasively. The present study sought to investigate the impact of ticagrelor and prasugrel on the incidence and pattern of urgent revascularization in acute coronary syndromes (ACS) patients undergoing percutaneous coronary intervention (PCI). METHODS AND RESULTS: This post-hoc analysis of the ISAR-REACT 5 trial included all ACS patients who underwent PCI...
May 13, 2024: Clinical Research in Cardiology: Official Journal of the German Cardiac Society